Ligand completes acquisition of XOMA for $39 per share
Ligand Pharmaceuticals completed the acquisition of XOMA Royalty for $39.00 per share following the deal's closing. The transaction includes a contingent value right for pending litigation proceeds.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day